Teerapong Siriboonpiputtana
Overview
Explore the profile of Teerapong Siriboonpiputtana including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
72
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rujirachaivej P, Siriboonpiputtana T, Choomee K, Supimon K, Sangsuwannukul T, Songprakhon P, et al.
J Transl Med
. 2025 Jan;
23(1):54.
PMID: 39806405
Background: Multiple myeloma (MM) is an incurable plasma cell malignancy with increasing global incidence. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA has shown efficacy in relapsed or refractory MM,...
2.
Thangrua N, Siriboonpiputtana T, Rerkamnuaychoke B, Chareonsirisuthigul T, Korkiatsakul V, Pongphitcha P, et al.
Int J Lab Hematol
. 2024 Oct;
47(1):130-139.
PMID: 39357526
Introduction: Ph-like ALL has gene expression profile similar to Ph-positive ALL but without the BCR::ABL1 fusion. The disease presents higher rates of severe clinical features and is associated with unfavorable...
3.
Kiatprungvech N, Sangkum P, Malinee R, Sommaluan S, Korkiatsakul V, Worawichawong S, et al.
Pract Lab Med
. 2024 Jun;
40:e00410.
PMID: 38867760
Objectives: While recent studies have demonstrated several genetic alterations are associated with pathogenesis of RCC, the significance of cyclin-dependent kinase inhibitor 2A and cyclin-dependent kinase inhibitor 2B in tumorigenesis of...
4.
Rujirachaivej P, Siriboonpiputtana T, Luangwattananun P, Yuti P, Wutti-In Y, Choomee K, et al.
Clin Exp Med
. 2024 Apr;
24(1):90.
PMID: 38683232
Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the rapid proliferation of malignant plasma cells within the bone marrow. Standard therapies often fail due to patient resistance. The...
5.
Kongruang A, Limsuwanachot N, Magmuang S, Areesirisuk P, Niparuck P, Siriboonpiputtana T, et al.
Hematology
. 2023 Sep;
28(1):2256199.
PMID: 37695125
Objectives: We performed a feasibility study of an FDA-approved commercial ddPCR assay to measure :: in CML patients treated using TKI therapy. Methods: Assay performance of standard RQ-PCR and commercially...
6.
Limsuwanachot N, Rerkamnuaychoke B, Niparuck P, Singdong R, Kongruang A, Hirunpatrawong P, et al.
J Mass Spectrom Adv Clin Lab
. 2023 May;
28:122-132.
PMID: 37128502
Introduction: The therapeutic strategy and management of chronic myeloid leukemia (CML) have rapidly improved with the discovery of effective tyrosine kinase inhibitors (TKIs) to target BCR::ABL1 oncoprotein. However, nearly 30%...
7.
Panachan J, Rojsirikulchai N, Pongsakul N, Khowawisetsut L, Pongphitcha P, Siriboonpiputtana T, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681607
amplification is the strongest predictor of high-risk neuroblastoma (NB). The standard procedure to detect status requires invasive procedures. Extracellular vesicles (EVs) contain molecular signatures of originated cells, present in biofluids,...
8.
Niparuck P, Police P, Noikongdee P, Siriputtanapong K, Limsuwanachot N, Rerkamnuaychoke B, et al.
Diagn Pathol
. 2021 Oct;
16(1):100.
PMID: 34717674
Objectives: TP53 mutation is found frequently in therapy related acute myeloid leukemia (AML)/ myelodysplastic syndrome (MDS), AML and MDS patients with monosomy or complex karyotype. However, the prevalence and treatment...
9.
Chiangjong W, Panachan J, Vanichapol T, Pongsakul N, Pongphitcha P, Siriboonpiputtana T, et al.
Biomedicines
. 2021 Aug;
9(8).
PMID: 34440185
Chemotherapy in childhood leukemia is associated with late morbidity in leukemic survivors, while certain patient subsets are relatively resistant to standard chemotherapy. It is therefore important to identify new agents...
10.
Kamseng P, Siriboonpiputtana T, Puavilai T, Chuncharunee S, Paisooksantivatana K, Chareonsirisuthigul T, et al.
Pathol Oncol Res
. 2021 Jul;
27:606567.
PMID: 34257568
Multiple myeloma (MM) patients considered to be at high cytogenetic risk commonly fail to respond to standard treatment. A thorough understanding of the molecular mechanism of MM development is, therefore,...